FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart

Bagsværd, Denmark, 6 November 2012 Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the New Drug Applications (NDA) for insulin degludec and insulin degludec/insulin aspart, which will take place on 8 November 2012. The briefing documents from Novo Nordisk and the FDA, which will form the basis for the Advisory Committee's discussion, provide an overview of the non-clinical and clinical data for insulin degludec and insulin degludec/insulin aspart for the treatment of diabetes. The briefing materials can be accessed on the FDA webpage here Further information Media: Mike Rulis +45 3079 3573 [email protected] Ambre Morley (US) +1 609 216 5240 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company Announcement no. 71 2012

The release as fetched from its publisher. novonordisk.com ↗